Log In Sign up
The largest database of trusted experimental protocols

Pegasys

Manufactured by Genentech
Visit Supplier
Sourced in United States

Pegasys is a laboratory product manufactured by Genentech. It is a molecular biology tool used for protein expression and purification. Pegasys is designed to facilitate the production and isolation of recombinant proteins in a laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

Ruxolitinib, by Novartis (1 mentions) Jakavi, by Novartis (1 mentions) Pegintron, by Merck Group (1 mentions)

2 protocols using pegasys

1

Combination Therapy for Myeloproliferative Neoplasms

Check if the same lab product or an alternative is used in the 5 most similar protocols
Initial therapy was PEG‐IFNα2a (Pegasys®; Genentech (Roche), South San Francisco, CA, USA) 45 μg or PEG‐IFNα2b (PegIntron®; Merck Sharp & Dohme, Hertfordshire, UK) 35 μg once weekly subcutaneously and ruxolitinib (Jakavi®; Novartis, Basel, Switzerland) 20 mg BID orally, the ruxolitinib dose being dependent on the platelet count. The doses and dose schedules were modified based on toxicity or lack of efficacy. If needed, patients were phlebotomized to reach the target hematocrit of <0.45 (males) or <0.42 (females). All patients received aspirin 75 mg daily unless contraindicated. Baseline investigations and initiation of CT were preceded by a wash‐out period of seven days from discontinuation of previous MPN‐directed therapy.
Mikkelsen S.U., Kjær L., Bjørn M.E., Knudsen T.A., Sørensen A.L., Andersen C.B., Bjerrum O.W., Brochmann N., Fassi D.E., Kruse T.A., Larsen T.S., Mourits‐Andersen H.T., Nielsen C.H., Pallisgaard N., Thomassen M., Skov V, & Hasselbalch H.C. (2018). Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 7(8), 3571-3581.
+ Open protocol
+ Expand
2

PegIFNα Administration for GVHD Prevention

Check if the same lab product or an alternative is used in the 5 most similar protocols
PegIFNα (PEGASYS; Genentech) was administered subcutaneously on day −1 before HCT, as well as on days 14, 28, and 42 (±7 days). Treatment was temporarily held for grade ≥ II acute GVHD and was discontinued for grades III to IV.
Magenau J.M., Peltier D., Riwes M., Pawarode A., Parkin B., Braun T., Anand S., Ghosh M., Maciejewski J., Yanik G., Choi S.W., Talpaz M, & Reddy P. (2021). Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 5(23), 5047-5056.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!